CagriSema Early Response Impresses but Post Hoc Data Cannot Carry Payer Approval
Clinical Trial Updates

CagriSema Early Response Impresses but Post Hoc Data Cannot Carry Payer Approval

Published : 17 Nov 2026

The Overview
Novo Nordisk announced positive post hoc findings from its Phase III REDEFINE 1 trial, evaluating the investigational combination therapy CagriSema in 3,417 adults with overweight or obesity and comorbidities over 68 weeks. The study, which compared subcutaneous CagriSema against semaglutide, cagrilintide, and placebo, revealed that 67.8% of participants on CagriSema achieved early responder status, defined as losing at least 5% of baseline body weight by week eight. These early responders demonstrated a mean weight reduction of 25.4% at week 68, significantly higher than the 17.8% observed in delayed responders. Additionally, 73.1% of CagriSema recipients reported meaningful improvements in physical function. The safety profile showed gastrointestinal effects in 79.6% of CagriSema patients, mostly mild-to-moderate and transient, leading to discontinuation in 5.9% of recipients.
Knolens Analysis

Post hoc REDEFINE 1 stratification reframes CagriSema around prediction rather than proven superiority, with 67.8% reaching at least 5% loss by week eight and those early responders averaging 25.4% loss at week 68 versus 17.8% in delayed responders, alongside 73.1% reporting meaningful physical function improvement. [1] The trial itself was a Phase 3 RCT in 3,417 adults with overweight or obesity and comorbidities over 68 weeks against semaglutide, cagrilintide and placebo, with confirmatory secondaries including 20%, 25% and 30% thresholds, positioning against semaglutide 2.4 mg monotherapy, cagrilintide 2.4 mg monotherapy and indirect tirzepatide 15 mg which showed -17.97% versus -17.84% for CagriSema in network meta-analysis. [2][1] Payer history is hostile to weight loss alone: semaglutide secured UK cost-effectiveness at £14,827 per QALY gained yet required a 67% price cut in Canada from $185,646 per QALY to meet a $50,000 threshold with over $40 million year-one impact, while the Netherlands advised non-inclusion for lack of substantiated cost-effectiveness. [3] Regulatory filing will need primary randomized contrasts of -20.4% versus -3.0% and -13.7% versus -3.4% in diabetes, full serious adverse event profiles beyond 79.6% transient gastrointestinal effects with 5.9% discontinuation, durability beyond 68 weeks, and cardiovascular outcomes, because no closely comparable amylin plus GLP-1 precedent exists to borrow approval or HTA credibility from, leaving tolerability burden and missing economics as the binding gap. [1][4]

Phase 3 REDEFINE 1 post hoc responder split (25.4% vs 17.8%) and 73.1% function signal lack primary arm-level contrasts and durability beyond 68 weeks.

At a Glance
Indicationobesity or overweight and comorbidities
DrugCagriSema
Mechanism of Actionamylin analogue and glucagon-like peptide-1 receptor agonist (GLP-1RA)
CompanyNovo Nordisk
Trial PhasePhase III
Trial AcronymREDEFINE 1
NCT IDNCT05567796
CategoryClinical Trial Event
Sub CategoryTopline Results Positive
Therapeutic AreaEndocrinology & Metabolic Diseases
Study Duration68 weeks
Patient Population Size3,417 patients
Comparator Armssemaglutide 2.4mg, cagrilintide 2.4mg, and placebo
DosageCagriSema 2.4mg/2.4mg
Early Responder Definitionlosing at least 5% of their baseline body weight by week eight
Mean Weight Reduction (Early Responders)25.4% at week 68
Regulatory Submission DateDecember 2025
Regulatory AgencyUS Food and Drug Administration (FDA)
Expected Regulatory Decisionfourth quarter of 2026
Conference NameObesityWeek 2026

Novo Nordisk Reports Positive CagriSema Phase III REDEFINE 1 Post Hoc Findings

Novo Nordisk announced positive post hoc findings from its Phase III REDEFINE 1 trial, evaluating the investigational combination therapy CagriSema in 3,417 adults with overweight or obesity and comorbidities over 68 weeks. The study, which compared subcutaneous CagriSema against semaglutide, cagrilintide, and placebo, revealed that 67.8% of participants on CagriSema achieved early responder status, defined as losing at least 5% of baseline body weight by week eight. These early responders demonstrated a mean weight reduction of 25.4% at week 68, significantly higher than the 17.8% observed in delayed responders. Additionally, 73.1% of CagriSema recipients reported meaningful improvements in physical function. The safety profile showed gastrointestinal effects in 79.6% of CagriSema patients, mostly mild-to-moderate and transient, leading to discontinuation in 5.9% of recipients.

  • The post hoc analysis of REDEFINE 1 highlighted that 67.8% of patients treated with CagriSema achieved early responder status, defined as losing at least 5% of their baseline body weight within the first eight weeks. This early response was strongly predictive of greater overall weight loss, with early responders achieving a mean weight reduction of 25.4% by week 68, compared to 17.8% for delayed responders. Furthermore, 73.3% of early responders attained at least 20% total weight reduction at week 68.
  • Beyond weight loss, CagriSema demonstrated significant improvements in patient-reported physical function. Using the Impact of Weight on Quality of Life-Lite Clinical Trials Version questionnaire, 73.1% of CagriSema recipients reported meaningful enhancements in physical function at week 68, a substantial increase compared to 49.1% in the placebo group. This indicates a positive impact on the overall quality of life for patients.
  • The safety data from the REDEFINE 1 trial indicated that adverse events led to treatment discontinuation in 5.9% of CagriSema recipients, compared to 3.5% with placebo. Gastrointestinal effects were the most common adverse events, occurring in 79.6% of patients on CagriSema versus 39.9% on placebo. These events, including nausea, constipation, and vomiting, were predominantly mild-to-moderate and transient, aligning with the known profiles of GLP-1 receptor agonists.
  • CagriSema, a combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a glucagon-like peptide-1 receptor agonist), is currently under regulatory review. Novo Nordisk submitted a New Drug Application (NDA) to the US FDA in December 2025, with an agency decision anticipated in the fourth quarter of 2026. This dual-action mechanism aims to provide comprehensive metabolic benefits for patients with obesity or overweight.

CagriSema's Dual-Action Approach in the Evolving Obesity Pipeline

Recent trials are evaluating multimodal combinations that pair GLP-1 receptor agonists with amylin analogues, GIP and glucagon receptor agonists, calcitonin receptor agonists, and SGLT2 inhibitors to enhance weight loss and address comorbidities. These approaches include unimolecular dual and triple agonists as well as co-administration of separate agents targeting multiple eating behavior and metabolic pathways simultaneously.

  • Combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration as CagriSema, currently in phase III development, with a combination of semaglutide with the amylin analogue cagrilintide (CagriSema) having shown strong efficacy.

  • Triple agonists targeting GLP-1, GIP, and glucagon receptors, including retatrutide as the most advanced candidate, which achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks, with HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤6.5%, and 82% reduction in hepatic steatosis.

  • Dual amylin and calcitonin receptor agonist (DACRA) KBP-066A in combination with the GLP-1R agonist semaglutide or the sodium-glucose co transporter-2 inhibitor (SGLT2i) empagliflozin, where KBP-066A and semaglutide lowered body weight by 13% and 9.7% while KBP-066A + semaglutide reduced body weight by 21% in HFD rats, and combinations significantly lowered fasting blood glucose and HbA1C (%) levels in ZDF rats.

  • GLP1ra and SGLT2i combination therapy for early biomarkers of diabetes kidney disease, with significant reductions in HbA1c (1.16%), weight (5.17 kg) and systolic blood pressure (8.13 mmHg) at 26 weeks, reduction in UACR of 15.14 mg/g (95% CI 8.50-22.4), and triple therapy with metformin + GLP1-RA + SGLT2-I initiated when glycated hemoglobin target is not reached.

  • Combination anti-obesity medication regimens including glucagon-like peptide-1 receptor agonists, including phentermine, topiramate, and metformin with added semaglutide resulting in a 32.5% total body weight reduction, and subgroup analysis suggesting combination therapy had more pronounced effects on outcomes than monotherapy in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery.

REDEFINE 1: Unpacking CagriSema's Efficacy and Early Response

Key obesity and overweight trials span pharmacologic and digital interventions, ranging from early dose-finding to long-term phase 3 designs in populations with diabetes, prediabetes, and cardiometabolic risk factors. Primary endpoints center on absolute and percent weight change and categorical ≥5% loss, with glycemic, anthropometric, and cardiometabolic measures as key secondaries. Safety evaluation consistently captures gastrointestinal tolerability, adverse events, and treatment discontinuation.

Trial / Population Design Treatment Arms Duration Primary Endpoint Secondary and Safety Endpoints
Hanslim in obese patients, BMI more than 30 kg/m or BMI 27 to 29.9 kg/m and one or more risk factors such as hypertension, diabetes, or hyperlipidemia, n=165 Randomized, double-blinded, multicenter, multidose, placebo-controlled, phase IIb clinical trial with 1:1:1 allocation and 4 scheduled visits High-dose Hanslim vs low-dose Hanslim vs placebo, 2 tablets 2 times per day 12-week treatment period Difference in the proportion of participants who lost weight by more than 5% from baseline at 12 weeks compared to placebo Body weight, BMI, body-fat percentage, fat mass, skeletal-muscle mass, edema index, waist circumference, hip circumference, waist-hip ratio, serum lipid, blood glucose, C-reactive protein, total score of Korean version of obesity-related quality of life; adverse events, laboratory test results, vital sings, and electrocardiography
Liraglutide in obesity without type 2 diabetes, 18-65 years, BMI 30-40 kg/m2, n=564, 19 sites in Europe Double-blind, placebo-controlled 20-week trial with open-label orlistat comparator, 500 kcal per day energy-deficit diet and increased physical activity including 2-week run-in, 84-week open-label extension followed Liraglutide 1.2 mg vs 1.8 mg vs 2.4 mg vs 3.0 mg once a day subcutaneously vs placebo vs orlistat 120 mg three times a day orally 20 weeks plus 2-week run-in Weight change analysed by intention to treat Blood pressure, prevalence of prediabetes; nausea and vomiting, adverse events and discontinuation
RIO-Diabetes with rimonabant in overweight/obese type 2 diabetes on metformin or sulfonylureas, BMI 27 to 40, HbA1c 6.5% to 10.0%, n=1,047, 151 centers in 11 countries 1-year, randomized, double-blind, placebo-controlled, parallel-group study with hypocaloric diet 600 kcal/day deficit and 4-week placebo plus diet run-in Placebo vs rimonabant 5 mg vs 20 mg once daily 1 year Absolute change in weight from baseline, change in waist circumference, HbA1c reductions Prevalence of metabolic syndrome and its constituents, systolic blood pressure, C-reactive protein, fasting glucose, high-density lipoprotein cholesterol, adiponectin
Taranabant in overweight and obese type 2 diabetes, ages ≥18 and ≤75 years, BMI ≥27 kg/m2 and ≤43 kg/m2, HbA1c ≥7.0 and ≤10.0%, on no antihyperglycaemic agent or stable metformin ≥1500 mg/day Multicenter, double-blind, randomized, placebo-controlled study with 2-week placebo run-in Placebo (N=156) vs taranabant 0.5-mg (N=155) vs 1-mg (N=157) vs 2-mg (N=155) once daily 52 weeks Changes from baseline in body weight and HbA1c at Week 36, results at Week 52 as key secondary endpoints Proportion who lost ≥5 and ≥10% of baseline body weight; adverse experiences in gastrointestinal, nervous system-related, and psychiatric organ systems
Maridebart cafraglutide phase 2 in obesity cohort (n=465, mean BMI 37.9) and obesity with type 2 diabetes cohort (n=127, mean BMI 36.5), total 592 Phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial in 11 groups as two cohorts Obesity cohort 3:3:3:2:2:2:3 to 140, 280, or 420 mg every 4 weeks without dose escalation vs 420 mg every 8 weeks vs 420 mg every 4 weeks with 4-week escalation vs 420 mg every 4 weeks with 12-week escalation vs placebo; obesity-diabetes cohort 1:1:1:1 to 140, 280, or 420 mg every 4 weeks vs placebo, subcutaneously 52 weeks Percent change in body weight from baseline to week 52 Change in glycated hemoglobin level; gastrointestinal adverse events, safety signals
SURMOUNT-1 with tirzepatide in obesity with prediabetes, n=1,032 of 2,539 Phase 3, double-blind, randomized, controlled trial with 17-week off-treatment period after treatment Tirzepatide 5 mg vs 10 mg vs 15 mg once-weekly vs placebo in 1:1:1:1 ratio 176 weeks treatment plus 17-week off-treatment period Percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods Most common adverse events were gastrointestinal, mild to moderate in severity during dose-escalation period in first 20 weeks; 3-year safety outcomes
DEMETRA digital therapy in obesity, 18-65 years, BMI 30-45 kg/m2, n=246, 2 obesity centers in Italy Prospective, multicenter, pragmatic, randomized, double-arm, single-blind, placebo-controlled trial with Mediterranean-style low-calorie diet 800 kcal/day deficit Digital Therapeutics for Obesity app with personalized diet, exercise, and psycho-behavioral support vs placebo app allowing log data without feedback 6 months 6-month absolute weight change Percent weight change, changes in BMI, waist circumference, blood pressure, glucose metabolism, lipid profile, adherence

Assessing CagriSema's Safety Profile and Patient-Reported Outcomes

Published data consistently characterize CagriSema as having a primarily gastrointestinal tolerability burden with comparable serious adverse event rates to monotherapy controls. Across overweight/obesity and type 2 diabetes populations, combination therapy improves efficacy while increasing selected non-serious events and treatment discontinuations.

  • Gastrointestinal events predominate: Adverse events were primarily gastrointestinal, with pooled analyses showing more frequent gastrointestinal adverse events for CagriSema versus semaglutide, cagrilintide, or placebo, including increased nausea [RR 1.64 (95% CI: 1.01, 2.66)] and overall gastrointestinal risk [RR: 1.32]; gastrointestinal adverse events and vomiting were significantly higher with CagriSema compared to semaglutide 2.4 mg weekly.

  • Administration-site reactions increased: Combination therapy increased administration-site conditions versus semaglutide [RR 3.27 (95% CI: 1.27, 8.46)], described as injection-site reactions alongside gastrointestinal events.

  • Serious and treatment-emergent events largely comparable: Treatment-emergent and serious adverse events were comparable between groups in multiple meta-analyses, with no increase in serious adverse events versus semaglutide, cagrilintide, or placebo in pooled analyses of 7 RCTs (n = 8,069) and 3 RCTs (n = 3545).

  • Discontinuations and systemic tolerability signals: Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); fatigue risk increased with CagriSema (risk ratio 3.2; 92 more per 1000 over one year).

CagriSema's Potential Impact on the Obesity Treatment Landscape

Trial data over the past five years show a shift toward dual-pathway and combination incretin therapies achieving substantial weight reduction in adults with overweight or obesity. In a network meta-analysis of 25 trials involving 12 interventions, tirzepatide 15 mg resulted in the greatest percent weight reduction (MD -17.97%), followed by CagriSema (MD -17.84%) and semaglutide 7.2 mg (MD -14.66%). At the ≥20% weight-loss threshold, CagriSema demonstrated marked superiority (RR 27.82), followed by tirzepatide 15 mg (RR 23.70). These findings align with individual Phase 3 results, including SURMOUNT-CN in Chinese adults where the mean change in body weight at week 52 was -13.6% (95% CI, -15.8% to -11.4%) with tirzepatide 10 mg, -17.5% (95% CI, -19.7% to -15.3%) with tirzepatide 15 mg, and -2.3% with placebo, with 87.7% with tirzepatide 10 mg, 85.8% with tirzepatide 15 mg, and 29.3% with placebo achieving body weight reductions of 5% or greater, and a SURMOUNT-1 Japanese subpopulation where percent change was -12.0% (1.7%), -22.4% (1.7%), -22.1% (1.6%), and -0.3% (1.6%) for tirzepatide 5-, 10-, 15-mg and placebo, with 91.7%, 100%, and 96.6% versus 15.4% achieving ≥5% weight reduction at week 72.

The landscape has also expanded to address maintenance of reduction, diverse populations, and alternative formulations. In SURMOUNT-4, participants who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%, with mean percent weight change from week 36 to week 88 of -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]), and 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo, with overall mean weight reduction from week 0 to 88 of 25.3% for tirzepatide and 9.9% for placebo. In SURMOUNT-MAINTAIN, the model-based estimate percent change in bodyweight from baseline to week 112 was -21.9% (95% CI -23.5 to -20.3) with maximum tolerated dose (estimated treatment difference [ETD] -12.0% [95% CI -13s·8 to -10·1]), -16·6% (95% CI -18·0 to -15·1) with 5 mg tirzepatide (ETD -6·6 [95% CI -8·3 to -5·0]), versus -9·9% (95% CI -11·1 to -8·8) with placebo. Oral semaglutide, 50 mg, in the OASIS 2 trial in Japan and South Korea showed a mean (SEM) percentage change of -14.3% (0.8) vs -1.3% (1.1) with placebo (estimated treatment difference, -13.07 percentage points; 95% CI, -15.61 to -10.52), with 107 of 127 [84.3%] vs 11 of 64 [17.2%] achieving 5% or greater reductions, while SUSTAIN and PIONEER demonstrated significant reductions in HbA1c, body weight, and major adverse cardiovascular events (MACE), and STEP trials showed up to 20% weight loss alongside improvements in obesity-related comorbidities.

Safety and cardiometabolic effects reported across trials indicate gastrointestinal events as the predominant tolerability issue with rare serious complications. Gastrointestinal adverse events increased with all treatments (RR 1.33-1.91), and treatment discontinuation was highest with semaglutide 7.2 mg (RR 3.09), while serious adverse events remained comparable to placebo across all regimens. In SURMOUNT-MAINTAIN, the most common adverse events with tirzepatide were gastrointestinal events, which were mostly mild to moderate in severity and mostly occurred during dose escalation, and in SURMOUNT-CN most were mild to moderate in severity, with few events leading to treatment discontinuation (<5%). Cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL, with semaglutide exhibiting renoprotective, anti-inflammatory, and potential hepatoprotective effects and emerging evidence in non-alcoholic fatty liver disease (NAFLD), heart failure, polycystic ovary syndrome (PCOS), obstructive sleep apnea (OSA), alcohol use disorder (AUD), and Alzheimer's disease.

Frequently Asked Questions

What is the mechanism of action of CagriSema in managing obesity and related comorbidities?
CagriSema is a co-formulation combining cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist. This dual mechanism targets multiple pathways involved in appetite regulation, satiety, and glucose homeostasis. Cagrilintide primarily reduces appetite and increases satiety, while semaglutide further enhances satiety, slows gastric emptying, and improves insulin secretion and glucose metabolism.
How does CagriSema differentiate from existing pharmacotherapies for weight management?
CagriSema offers a unique dual-agonist approach by combining an amylin analog with a GLP-1 receptor agonist, which is distinct from single-mechanism therapies. This synergistic action is designed to provide more profound and sustained weight loss compared to either component alone. The combined effect aims to address multiple physiological drivers of obesity and metabolic dysfunction more comprehensively.
What are the potential clinical benefits of CagriSema for patients with obesity or overweight and associated comorbidities?
CagriSema is anticipated to provide substantial weight reduction, which can lead to significant improvements in obesity-related comorbidities. These benefits may include better glycemic control in patients with type 2 diabetes, reductions in blood pressure, and improvements in lipid profiles. The comprehensive metabolic effects could also contribute to a reduced risk of cardiovascular events and enhanced overall patient health.
What are the key considerations for patient selection and long-term management with CagriSema?
Patient selection for CagriSema typically involves individuals with obesity (BMI ≥30 kg/m²) or those who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Long-term management emphasizes the integration of CagriSema with comprehensive lifestyle interventions, including diet and exercise, to optimize and sustain weight loss outcomes. Regular monitoring for efficacy and safety is also crucial throughout the treatment duration.

References

  1. [1] Horn DB, Aronne LJ et al.. Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN. Obesity (Silver Spring, Md.). 2025 Oct. 40916045
  2. [2] Olubodun T, Osundina MA et al.. Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes. PloS one. 2026. 42594084
  3. [3] Astrup A, Rössner S et al.. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (London, England). 2009 Nov 7. 19853906
  4. [4] Ismail A, Amer MS et al.. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions. World journal of gastrointestinal pharmacology and therapeutics. 2025 Sep 5. 40937289
  5. [5] McMahon FG, Weinstein SP et al.. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of human hypertension. 2002 Jan. 11840224
  6. [6] Aroda VR, Bain SC et al.. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The lancet. Diabetes & endocrinology. 2017 May. 28344112
  7. [7] Velji-Ibrahim J, Radadiya D et al.. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. Journal of obesity. 2025. 41211586
  8. [8] Jia IT, Bloomfield GC et al.. Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis. Surgical endoscopy. 2025 Dec. 41028671
  9. [9] Naz F, Qaiser F et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis. Medicine. 2026 Jul 31. 42536519
  10. [10] Vilarrasa N, Pellitero S. GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases. Medicina clinica. 2025 Dec. 41016281
  11. [11] Dell'osso B, Timtim S et al.. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. Journal of affective disorders. 2013 Aug 15. 23261131
  12. [12] Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert opinion on investigational drugs. 2025 Mar. 40022548
  13. [13] Lin J, Wang H et al.. Obstructive sleep apnoea is independently associated with non-alcoholic fatty pancreatic disease. Scandinavian journal of gastroenterology. 2024 Nov. 39324583
  14. [14] Hamarsheh S, Jaber AR et al.. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism. 2026 Jul. 42207966
  15. [15] Wang Y, Liu J et al.. Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control. Advances in nutrition (Bethesda, Md.). 2026 Jun. 42106160
  16. [16] Jensterle M, Rizzo M et al.. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in therapy. 2022 Jun. 35503498
  17. [17] Elmaleh-Sachs A, Schwartz JL et al.. Obesity Management in Adults: A Review. JAMA. 2023 Nov 28. 38015216
  18. [18] Tahara A, Takasu T. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents. Life sciences. 2018 Mar 15. 29425766
  19. [19] Cobbold JF, Miller H et al.. The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus. The lancet. Gastroenterology & hepatology. 2026 Jul. 42070581
  20. [20] Carretero Gómez J, Ena J et al.. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents. International journal of clinical practice. 2020 Oct. 32533906

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts